<p>After initiation of HAART, the plasma viral load undergoes a multiphasic decay and declines to below the detection limit (e.g., 50 RNA copies/mL) of standard assays after several months. A low level of viremia below 50 copies/mL may persist in patients for many years despite apparently effective antiretroviral treatment. Intermittent viral blips with transient HIV-1 RNA above the limit of detection are usually observed in well-suppressed patients.</p
To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving ...
To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus ...
Residual HIV viremia, defined by low levels of plasma HIV RNA with enhanced-sensitivity assays, may ...
UnlabelledWe measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of sing...
BACKGROUND: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combinatio...
BACKGROUND: It has been suggested that low-level viremia or blips in HIV-infected patients on antire...
BACKGROUND Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combinat...
In human immunodeficiency virus (HIV)–infected patients successfully treated with highly active anti...
Retrospective analysis of 22 523 people with HIV-1 receiving antiretroviral therapy indicates that b...
Objective: To investigate immunologic, virologic, and clinical consequences of episodes of transient...
BACKGROUND: It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral lo...
It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral load (VL) of ...
Early recognition of virologic failure in patients with extensive drug resistance receiving salvage-...
<div><h3>Background</h3><p>Early treatment of acute HIV infection with highly active antiretroviral ...
Rapid suppression of plasma HIV RNA and sustained increase in CD4 cell count following highly active...
To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving ...
To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus ...
Residual HIV viremia, defined by low levels of plasma HIV RNA with enhanced-sensitivity assays, may ...
UnlabelledWe measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of sing...
BACKGROUND: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combinatio...
BACKGROUND: It has been suggested that low-level viremia or blips in HIV-infected patients on antire...
BACKGROUND Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combinat...
In human immunodeficiency virus (HIV)–infected patients successfully treated with highly active anti...
Retrospective analysis of 22 523 people with HIV-1 receiving antiretroviral therapy indicates that b...
Objective: To investigate immunologic, virologic, and clinical consequences of episodes of transient...
BACKGROUND: It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral lo...
It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral load (VL) of ...
Early recognition of virologic failure in patients with extensive drug resistance receiving salvage-...
<div><h3>Background</h3><p>Early treatment of acute HIV infection with highly active antiretroviral ...
Rapid suppression of plasma HIV RNA and sustained increase in CD4 cell count following highly active...
To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving ...
To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus ...
Residual HIV viremia, defined by low levels of plasma HIV RNA with enhanced-sensitivity assays, may ...